| |
INFERGEN® (interferon alfacon-1), also known as consensus
interferon, is marketed for the treatment of adults with chronic hepatitis C
virus (HCV) infections. It is currently the only FDA approved, bio-optimized
interferon developed through rational drug design and the only interferon
with data in the label specifically for non-responding or refractory
patients. InterMune's sales force re-launched Infergen in January 2002 with
an active campaign to educate U.S. hepatologists about the safe and
appropriate use of Infergen, which represents new hope for the more than 50
percent of HCV patients who fail other currently available therapies.
All alpha interferons, including interferon alfacon-1,
cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune,
ischemic, and infectious disorders. Patients should be monitored closely
with periodic clinical and laboratory evaluations. Patients with
persistently severe or worsening symptoms of these conditions should be
withdrawn from therapy. In many but not all cases, these disorders resolve
after stopping interferon alfacon-1 therapy. See WARNINGS, and ADVERSE
REACTIONS in full
prescribing information (Adobe
Acrobat required). |
